| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44008577 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44032094 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44000853 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44007297 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44006841 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44012767 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44019581 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44019582 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44019583 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
| TVIS44019584 | HTLV-1 | ENSG00000113448.21 | protein_coding | PDE4D | No | No | 5144 | A0A140VJR0 Q08499 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PDE4D |
|---|---|
| DrugBank ID | DB00131 |
| Drug Name | Adenosine phosphate |
| Target ID | BE0001287 |
| UniProt ID | Q08499 |
| Regulation Type | product of |
| PubMed IDs | 17088426 |
| Citations | Terrin A, Di Benedetto G, Pertegato V, Cheung YF, Baillie G, Lynch MJ, Elvassore N, Prinz A, Herberg FW, Houslay MD, Zaccolo M: PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J Cell Biol. 2006 Nov 6;175(3):441-51. |
| Groups | Approved; Investigational; Nutraceutical; Withdrawn |
| Direct Classification | Purine ribonucleoside monophosphates |
| SMILES | NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1 |
| Pathways | Leigh Syndrome; Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Fatty Acid Metabolism; Gentamicin Action Pathway; Pyruvate Dehydrogenase Complex Deficiency; Purine Nucleoside Phosphorylase Deficiency; Hyperprolinemia Type II; Glutamate Metabolism; Clarithromycin Action Pathway; Argininosuccinic Aciduria; Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency); Hyperinsulinism-Hyperammonemia Syndrome; Butyrate Metabolism; Pyruvate Metabolism; Pentose Phosphate Pathway; Propanoate Metabolism; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Roxithromycin Action Pathway; Purine Metabolism; Ammonia Recycling |
| PharmGKB | PA164744376 |
| ChEMBL | CHEMBL752 |
